Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate

Journal of Urology

Volumn 157, Issue 4, 1997, Pages 1329-1334

  Smith Jr , Joseph A ^a   Lange, Paul H ^a   Janknegt, Rudi A ^a   Abbou, Claude C ^a   DeGery, Annie ^a  

^a NONE

Author keywords

hormones; prostatic neoplasms; survival; tumor markers, biological

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0030897726     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64963-2     Document Type: Article

References (16)

1. Eisenberger, M. A. and Nelson, W. G.: How much can we rely upon the level of PSA or an endpoint for evolution of clinical trials? A word of caution. J. Natl Cancer Inst., 88: 779, 1996.
2. Janknegt, R. A., Abbou, C. C., Bartoletti, R., Bernstein-Hahn, L., Bracken, B., Brisset, J. M., Calais Da Silva, F., Chisholm, G., Crawford, E. D., Debruyne, P. A., Dijkman, G. D., Frick, J., Goedhals, L., Knonagel, H. and Venner, P. M.: Orchiectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double-blind randomized trial. J. Urol., 149: 77, 1993.
3. Schmidt, J. D., Gibbons, R. P. and Johnson, D. E.: Chemotherapy of advanced prostatic cancer. Evaluation of response parameters. Urology, 7: 602, 1976.
4. Labasky, R. F. and Smith, J. A., Jr.: Management of pain and other symptoms of advanced prostatic cancer. Sem. Urol., 6: 311, 1988.
5. Smith, J. A., Jr. and Scaletscky, R.: Future directions in tumor marker technology for prostate cancer. Urol. Clin. N. Amer., 20: 771, 1993.
6. Crawford, E. D., Eisenberger, M. A., McCleod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med., 321: 419, 1989.
7. Denis, L. J., Carniero de Moura, J. L., Bono, A., Sylvester, R., Whelan, P., Newling, D. and Depauw, M.: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (38853). Urology, 42: 119, 1993.
8. Bertagna, C., De Géry, A., Hucher, M., Francois, J. P. and Zanirato, J.: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer: a meta-analysis of seven randomized double-blind trials (1056 patients). Brit. J. Urol., 73: 396, 1994.
9. Lowe, F. C. and Trauzzi, S. J.: Prostatic acid phosphatase in 1993: its limited clinical utility. Urol. Clin. N. Amer., 20: 589, 1993.
10. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
11. Matzkin, H., Eber, P., Todd, B., van der Zwaag, R. and Soloway, M. S.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer, 70: 2302, 1992.
12. Miller, J. I., Ahmann, F. R., Drach, G. W., Emerson, S. S. and Bottaccini, M. R.: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 147: 956, 1992.
13. 2 prostate cancer: prostate specific antigen (PSA) as a measure of outcome. Proc. Amer. Soc. Clin. Oncol., 12: 241, abstract 751, 1993.
14. Rana, A., Chisholm, G. D., Christodoulou, S., McIntyre, M. A. and Elton, R. A.: Audit and its impact in the management of early prostatic cancer. Brit. J. Urol., 71: 721, 1993.
15. Kelly, W. K., Scher, H. I., Mazumdar, M., Vladmis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607, 1993.
16. Sridhara, R., Eisenberg, M. and Reyno, L.: Predictive value of sequential PSA changes in patients with hormone refractory prostate cancer treated with suramin. J. Clin. Oncol., 12: 231A, 1993.